Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T21:45:42.702Z.
Calculation as of: 2026-10-06T21:45:42.702Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92c64d45da0f6188a1f90128b536bb11be3c3b1eef81eadefd65dadb391e1e70
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$5.21M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.24M
EV/Sales Ratio
0.73x
TTM Avg
1.63x
3Y Avg
1.96x
5Y Avg
36.60x
Market Cap
$5.12M
EV/Sales Ratio
161.37x
TTM Avg
289.54x
3Y Avg
289.54x
5Y Avg
289.54x
Market Cap
$5.32M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.35M
EV/Sales Ratio
10.13x
TTM Avg
29.50x
3Y Avg
46.21x
5Y Avg
38.89x
Market Cap
$4.97M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alzamend Neuro Inc (ALZN) | $5.21M | N/A | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | N/A | 974.76x | 727.03x | 628.61x |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | 0.73x | 1.63x | 1.96x | 36.60x |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | 161.37x | 289.54x | 289.54x | 289.54x |
| Soligenix, Inc. (SNGX)vs › | $5.31M | N/A | 2.85x | 161.09x | 86.59x |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | 10.13x | 29.50x | 46.21x | 38.89x |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | N/A | N/A | N/A | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.86M | N/A | 0.61x | 0.46x | 2.93x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
